Literature DB >> 13583918

Value of uricosuric agents and in particular of G. 28 315 in gout.

G D KERSLEY, E R COOK, D C TOVEY.   

Abstract

Entities:  

Keywords:  GOUT/therapy; PHENYLBUTAZONE/related compounds

Mesh：

Substances：

Year:  1958        PMID： 13583918      PMCID： PMC1007056          DOI： 10.1136/ard.17.3.326

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

1.  A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671.

Authors:  J J BURNS; T F YU; A RITTERBAND; J M PEREL; A B GUTMAN; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1957-03       Impact factor: 4.030

2.  Evaluation of uricosuric agents in chronic gout.

Authors:  M A OGRYZLO; J HARRISON
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

3.  Current principles of management in gout.

Authors:  A B GUTMAN; T F YU
Journal:  Am J Med       Date:  1952-12       Impact factor: 4.965

4.  Gout; observations on the effects of drugs on plasma uric acid and urinary uric acid.

Authors:  G D KERSLEY; L MANDEL; E BENE
Journal:  Ann Rheum Dis       Date:  1951-09       Impact factor: 19.103

5.  A modified technique for determining uric acid in blood and urine.

Authors:  D S BIDMEAD
Journal:  J Clin Pathol       Date:  1951-08       Impact factor: 3.411

6.  Therapeutic value of probenecid (benemid) in gout.

Authors:  L R PASCALE; A DUBIN; W S HOFFMAN
Journal:  J Am Med Assoc       Date:  1952-07-26

7.  Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects.

Authors:  T F YU; J H SIROTA; A B GUTMAN
Journal:  J Clin Invest       Date:  1953-11       Impact factor: 14.808
  7 in total
  9 in total

1.  Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.

Authors:  T F YU; A B GUTMAN
Journal:  J Clin Invest       Date:  1959-08       Impact factor: 14.808

2.  MUTUAL SUPPRESSION OF THE URICOSURIC EFFECTS OF SULFINPYRAZONE AND SALICYLATE: A STUDY IN INTERACTIONS BETWEEN DRUGS.

Authors:  T F YUE; P G DAYTON; A B GUTMAN
Journal:  J Clin Invest       Date:  1963-08       Impact factor: 14.808

3.  Uricosuric agents in the treatment of gout.

Authors:  G D KERSLEY; A R GIBBS
Journal:  Ann Rheum Dis       Date:  1960-12       Impact factor: 19.103

4.  Sulphinpyrazone in the treatment of arthritis associated with hyperuricaemia.

Authors:  E N GLICK
Journal:  Proc R Soc Med       Date:  1961-05

5.  Phenylbutazone and its derivatives with special reference to G.27202.

Authors:  F D HART; D BURLEY
Journal:  Br Med J       Date:  1959-04-25

6.  NEW DRUGS.

Authors: 
Journal:  Can Med Assoc J       Date:  1959-04-01       Impact factor: 8.262

Review 7.  Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.

Authors:  A K Pedersen; P Jakobsen; J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

8.  New Uricosuric Agent in the Treatment of Gout: para-Carboxybenzenesulpha-diethylamide (Urelim).

Authors:  D B Horn; M Thompson
Journal:  Ann Rheum Dis       Date:  1960-12       Impact factor: 19.103

9.  Comparison of the uricosuric effect of sulfinpyrazone (anturan) and zoxazolamine (flexin).

Authors:  D B MONTGOMERY; M A OGRYZLO
Journal:  Can Med Assoc J       Date:  1960-10-22       Impact factor: 8.262
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.